nference Revenue and Competitors

Boston, MA USA

Location

$145M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • nference's estimated annual revenue is currently $144.4M per year.(i)
  • nference's estimated revenue per employee is $281,400
  • nference's total funding is $145M.

Employee Data

  • nference has 513 Employees.(i)
  • nference grew their employee count by 32% last year.

nference's People

NameTitleEmail/Phone
1
Software EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is nference?

Powered by its artificial intelligence software platform, nferX, nference's mission is to synthesize the exponentially growing biomedical knowledge. nferX uses state-of-the-art neural networks (shallow and deep learning models) for real-time, automated extraction of knowledge from the commercial, scientific and regulatory body of literature. The platform enables a diverse set of applications ranging from R&D to commercial strategy and operations in the life sciences ecosystem. The long-term goal of the nferX platform is to become the connecting fabric of the various silos of information that exist across health care. Founded by Murali Aravamudan and Venky Soundararajan, Ph.D., nference is led by a multidisciplinary team of serial entrepreneurs from the tech and biotech worlds and PhDs in Biology/Genomics from MIT and Harvard Medical School. The investors in nference are Matrix Partners and Matrix Capital Management.

keywords:Biotechnology, Natural Language Processing, Artificial Intelligence / Machine Learning

$145M

Total Funding

513

Number of Employees

$144.4M

Revenue (est)

32%

Employee Growth %

N/A

Valuation

N/A

Accelerator

nference News

2022-04-06 - Third mRNA COVID-19 Vaccine Dose Appears to Be Safe

D., from nference in Cambridge, Massachusetts, and colleagues evaluated the safety of third-dose vaccination with U.S. Food and Drug...

2022-03-22 - nference Accelerates Self-Supervised Language Model ...

nference uses transformer AI models to employ self-supervised learning from large volumes of unstructured data without labels,...

2022-03-22 - Cerebras and nference Launch NLP Collaboration

nference uses transformer AI models to employ self-supervised learning from large volumes of unstructured data without labels, translating vast...

2021-03-23 - nference Study Reveals Pre-Existing Conditions to Be a Significant Factor in COVID Patients Who Are Hospitalized Post-Viral Clearance

CAMBRIDGE, Mass., March 23, 2021 /PRNewswire/ -- nference, the AI-driven health technology company, today announced publication in EClinicalMedicine of study "Pre-existing conditions are associated with COVID patients hospitalization, despite confirmed clearance of SARS-CoV-2 virus" that sheds ...

2021-03-10 - New nference Study Reveals Mortality and Racial Disparities in COVID-19 Anticoagulant Treatments

CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- nference, the AI-driven health technology company, today announced publication in EClinicalMedicine of "Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patie ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$93.5M5166%N/A
#2
$116.3M5175%N/A
#3
$66.9M5259%N/A
#4
$119.3M5301%N/A
#5
$142.8M5444%N/A